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1. Introduction 
Tumor suppressor genes and oncogenes are important regulatory genes which encode 
proteins regulating transitions in and out of the cell cycle and which also have a role in the 
gateway to terminal differentiation (Tripathy & Benz, 1992). Defects in tumor suppressor 
genes and oncogenes result in uncontrolled cell division, which leads to cancer (Tripathy & 
Benz, 1992). Oncogenes are mutated proto-oncogenes that have a role in malignancy of tumors 
and most frequently regulate cell cycle re-entry. Gain-of-function mutations result in 
transformation of proto-oncogenes into dominant oncogenes. Tumor suppressor genes encode 
proteins that suppress cell growth and most frequently result in exit from the cell cycle. Loss-
of-function mutations in tumor suppressor genes result in tumor malignancy and can account 
for hereditary cancers. Every gene has two alleles present in the genome (with a few 
exceptions in the hemizygous regions of the sex chromosomes). For tumor suppressor genes to 
be inactivated either deletion of one allele and somatic mutation of the other allele is required 
resulting in a loss of heterozygosity (Swellam et al., 2004), or somatic deletion of both of the 
alleles is required resulting in a complete loss of homozygosity (Quelle et al., 1997). Tumor 
suppressor genes can also be inactivated by hypermethylation of the gene resulting in 
promoter suppression so that genes can not be transcribed further (Herman et al., 1997). 
Telomere shortening and tumor suppressor gene promoter hyper-methylation can be used as 
potential breast cancer biomarkers (Radpour et al., 2010). 
Regulation of cell proliferation and differentiation is important in due course of growth and 
development of an organism. Cell proliferation is not an infinitely continuous process as 
cells undergo a finite number of cumulative population doublings (CPDs) in culture before 
entering replicative senescence (RS) (Hayflick, 1965). Cell replication or growth is controlled 
by a complex network of signals that control the cell cycle, the orderly sequence of events 
that all cells pass through as they grow to approximately twice their size, copy their 
chromosomes, and divide into two new cells. The cell cycle consists of 4 phases; G1, S, G2, 
and M phase (Enoch & Nurse, 1991). DNA duplication takes place in S phase and 
cytokinesis in M phase. G1 and G2 are gap phases, which provide the time for cells to 
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ensure suitability of the external and internal environment and preparation for DNA 
duplication and division. Cell cycle progression from one phase to another is controlled 
principally by cell cycle proteins; cyclins, the cofactors of cyclin dependent kinases (CDKs), 
a family of serine/threonine kinases (Afshari & Barrett, 1993). Cyclins are the cell cycle 
proteins, which bind to CDKs and activate them to function and enhance cell cycle 
progression (Pines & Hunter, 1991). Cyclin/CDK complexes are specific for each phase 
transition. In complex eukaryotic cells there are approximately 20 CDK related proteins. 
Complex combination of all these different CDKs and cyclins in different phases of the cell 
cycle provide tightly regulated control of cell cycle progression (Satyanarayana & Kaldis, 
2009). Levels of CDKs in cells vary little throughout the cell cycle, but cyclins, in contrast are 
periodically synthesized and destroyed in a timely manner to regulate the CDK’s activity 
during cell cycle (Malumbres & Barbacid, 2009).  
Early G1 phase progression is facilitated by CDK4/6 binding with cyclin D family proteins. 
These complexes phosphorylate members of the retinoblastoma protein (Rb) family (Rb, 
p130, and p107) (Sherr & Roberts, 1999). Phosphorylation of Rb results in release of E2F 
protein, which otherwise binds to Rb. E2F is a transcription factor, which activates E2F 
responsive genes, which are required for further cell-cycle progression in S phase 
(Weinberg, 1995). CyclinE/CDK2 complexes complete Rb phosphorylation and promote 
further progression of the cell cycle through late G1 phase. These complexes further activate 
E2F-mediated transcription and passage through the restriction point to complete G1/S 
phase transition (Sherr & Roberts, 1999). At the onset of S phase, cyclin A is synthesized, 
forms a complex with CDK2 and phosphorylates proteins involved in DNA replication 
(Petersen et al., 1999).  
During replication of DNA in S phase of the cell cycle, CDC6 and Cdt1 are recruited to 
recognition complexes. These factors help in the recruitment of mini-chromosome 
maintenance (MCM) proteins to replication origins which are known as pre-replicative 
complexes (preRC). In early S phase, preRC recruits the functional replication complex 
including DNA polymerase and associated processivity factors such as proliferating cell 
nuclear antigen (PCNA). Subsequent cell cycle transition takes place through the activity of the 
CDK1/cyclinA complex initiating prophase of mitosis (Furuno et al., 1999). Finally, activation 
of CDK1/cyclin B complex activity completes entry into mitosis (Riabowol et al., 1989).  
Along with the cyclins and CDKs, other proteins such as the tumor suppressor genes, the 
retinoblastoma protein (Rb), p53 and transcription factors such as the E2F proteins, play 
important roles in regulating cell cycle progression. The cell cycle has two important check 
points that occur at the G1/S and G2/M phase transitions (Hartwell & Weinert, 1989). These 
check points control cell cycle progression during normal proliferation and during stress, 
DNA damage, and other types of cellular dysfunction. At these cell cycle check points, 
cellular CDKs can be inhibited by cyclin-dependent kinase inhibitors (CKIs); thus, inhibiting 
and regulating cell cycle progression (Morgan, 1997). Rb can remain active suppressing 
downstream transcription factors if cyclin/CDKs are suppressed and p53 can directly 
activate CKI gene expression (Udayakumar et al., 2010). 
All of the CKIs are proven tumor suppressor genes or suspected of having this potential. Two 
CKI families which play important roles in regulating cell division are; the INK4 family and 
the KIP/CIP family (Vidal & Koff, 2000). INK4 family inhibitors inhibit CDK4 and CDK6 in 
association with cyclin D, while KIPs inhibit CDK1, CDK2 and CDK4 associations with cyclin 
A, cyclin B, and cyclin E. The INK4 family consists of p16 (INK4A), p15 (INK4B), p18 (INK4C), 
and p19 (INK4D). The KIP family consists of p21 (CIP1), p27 (KIP1), and p57 (KIP2).  
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1.1 INK4A/CDKN2A/p16 
p16 is an important CKI and a tumor suppressor gene encoded on the 9p21 region of the 
human genome, chromosome number 4 in mouse, and chromosome 11 in dogs (Serrano  
et al., 1993; Kamb et al., 1994; Asamoto et al., 1998; Fosmire et al., 2007) at the 
INK4A/ARF/INK4B locus. This gene locus is a 35kb multigene region which encodes three 
distinct major tumor suppressor genes, p15, p14ARF, and p16 (Sherr & Weber, 2000). 
INK4A/ARF/INK4B gene locus is repressed in young and normal cells by polycomb 
proteins and histone H3 lysine27 (H3K27) trimethylation (Kotake et al., 2007; Kia et al., 2008; 
Agger et al., 2009) and is induced during aging or by hyperproliferative oncogenic stimuli or 
stress. The INK4A/ARF locus has been speculated to have a global anti-aging effect by 
favoring cell quiescence and limiting cell proliferation (Matheu et al., 2009).  
The classic role of p16/INK4A/CDKN2A is to check the cell cycle in early G1 phase and 
inhibit further transition of the cell cycle from G1 to S phase as a component of a multi-
protein regulatory complex. During G1 phase, CDK4 and CDK6 form complexes with cyclin 
D1 which in turn phosphorylate the Rb protein family resulting in additional 
phosporylation by cyclin E/CDK complexes. These inhibitory phosphorylations of Rb cause 
release of the E2F transcription factor from Rb/E2F complexes. Rb otherwise inhibits 
transcription factor E2F (Weinberg, 1995). E2F is a transcription factor which initiates 
transcription of genes required for S phase such as DNA polymerase, thymidine kinase, 
dihydrofolate reductase, replication origin binding protein HsOrc1 and MCM (Lukas et al., 
1996). Action of p16 inhibits binding of CDK4/6 with cyclin D1 which leaves Rb, and Rb-
related proteins like p107 and p103, un-phosphorylated and E2F bound and inactive 
(Serrano et al., 1993; Walkley & Orkin, 2006). INK4 proteins cause both inhibitory structural 
changes and block activating structural changes to bound CDKs. p16 binds next to the ATP 
binding site of the catalytic cleft, opposite to the cyclin binding site, which results in a 
structural change in the cyclin binding site (Russo et al., 1998). p16/INK4A targets CDK4 
and CDK6, rather than the cyclin subunit, and actually competes with cyclin D1 for CDK 
binding. Binding of p16 results in changes in conformation of CDK proteins so that they can 
no longer bind cyclin D1 (Russo et al., 1998). p16 distorts the kinase catalytic cleft, interferes 
with ATP binding, and thus may also deactivate pre-assembled CDK4/6-cyclin D1 
complexes blocking their function (Russo et al., 1998). Binding sites for p16 and cyclin D1 on 
CDK4 are overlapping in some cases and are present near the amino terminus where a 
majority of the mutations in CDK4 are found. Mutations in the p16 binding site result in 
diminished capability of p16 binding to CDK4 and also compromise the binding of cyclin 
D1 to CDK4, which can also lead to melanoma (Coleman et al., 1997; Tsao et al., 1998). Other 
than inhibiting the pRb/E2F pathway, the very recently reported function of p16 is to 
downregulate CDK1 expression by upregulating miR-410 and miR-650 (Chien et al., 2011). 
CDK1 is an indispensable kinase which is most important for cell cycle regulation during 
G2/M phase (Santamaria et al., 2007). The regulation of CDK1 by p16 is post-transcriptional. 
Thus, p16 is an important tumor suppressor gene which regulates gene expression at 
different levels by modifying functional equilibrium of transcription factors, and 
consequently of miRNAs, and also by binding to post-transcriptional regulators (hnRNP 
C1/C2 and hnRNP A2/B1) (Souza-Rodrigues et al., 2007). The role of p16 in cell growth can 
also be attributed by irreversible repression of the hTERT (human telomerase) gene by 
increasing the amount of histone H3, trimethylated on lysine 27 (H3K27), bound to the 
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hTERT promoter (Bazarov et al., 2010). hTERT encodes the catalytic subunit of telomerase; 
therefore, p16 induction results in repression of telomerase and thus telomere shortening. 
Another binding partner important for cell growth inhibition by p16 is GRIM-19 (Gene 
associated with Retinoid-IFN-induced Mortality-19). GRIM-19 is a tumor suppressor gene 
mutations of which have been found in primary human tumors. GRIM-19 and p16 
synergistically inhibit cell cycle progression via the E2F pathway (Sun et al., 2010). 
2. Gene location and mapping of the p16 gene 
The region of the human chromosome, 9p21 encompassing the INK4A gene locus, 
corresponds to regions of dog chromosome 11, mouse chromosome 4, and rat chromosome 
5. These regions have been demonstrated to be frequently mutated in various types of 
cancer (Ruas & Peters, 1998; Sharpless, 2005). The INK4A gene locus also alternatively 
named the CDKN2B/CDKN2A or INK4A/ARF/INK4B locus, encodes three members of 
the INK4 family of cyclin dependent kinase inhibitors (CKIs), including p15, p16, and the 
MDM2 ubiquitin ligase inhibitor p14ARF (Gil & Peters, 2006). p15 has its own reading 
frame and is physically distinct, but p14ARF and p16 share a common second and third 
exon but each has a different and unique first exon (Kim & Sharpless, 2006). It has been 
reported that tandem gene duplication and rearrangement occurred during the evolution 
of INK4A (p16) and INK4B (p15) that are located 30 kbp apart on the same chromosome 
(Fig.1) (Sharpless, 2005).  
The INK4A gene was initially discovered to have three exons. Subsequent evidence 
identified an additional exon between the INK4B and INK4A genes, designated as exon1ǃ, 
that was alternatively spliced from INK4A exon 1 (Mao et al., 1995; Quelle et al., 1995; 
Stone et al., 1995a). This alternative exon 1ǃ was transcribed from a promoter different from 
the p16INK4A first exon (exon 1ǂ) and then spliced to the same second and third exons of 
INK4A to form a transcript, usually shorter than that encoding p16INK4A (Stone et al., 
1995b). The 1ǃ transcript encodes a completely different protein from p16 because splicing 
of exon 1ǃ to exon 2 allows translation from an alternative reading frame resulting in the 
different protein sequence (Fig. 2) (Quelle et al., 1995; Stone et al., 1995a).  
In most mammals this later protein is referred to as p14ARF (‘14’ indicates molecular weight 
of the protein and ARF for alternative reading frame). An ortholog of exon1ǃ in mouse and 
rat is longer than those from other mammals resulting in a larger protein and is designated 
p19ARF (Quelle et al., 1995). Thus, these two alternative INK4A transcripts (p16 and 
p14ARF/p19ARF) share a large overlapping nucleotide sequence for the common exons 2 
and 3 but result in structurally unrelated proteins due to presence of unique alternative first 
exons. Both have become important candidates for the study of novel cancer mechanisms. 
In dogs, the p16 and p14ARF transcripts derived from INK4A locus have not been fully 
elucidated. There are no full-length mRNAs or expressed sequence tags (ESTs) available that 
would completely define these transcripts. In addition this region of the chromosome is 
extremely GC-rich making it difficult to clone and sequence and causing a gap in the 
CanFam 2.0 genome assembly (Lindblad-Toh et al., 2005). The biological functions of these 
two proteins are fairly well understood compared to their genomic structure. Several lines 
of evidence suggest that both p16 and p14ARF act as potent tumor suppressors apart from 
their roles as cell cycle regulators during the G1 to S phase transition and p53 mediated cell 
cycle arrest, respectively. 
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Fig. 1. Evolution of mammalian CKIs.  Schematic representation of gene duplication and the 
evolution of CKIs (p16INK4A, p15INK4B, p18INK4C and p19INK4D) from a single ancestor 
INK4 gene. The chromosomal localization of INK4 genes are widely conserved across 
mammals. During the course of evolution, INK4C and INK4D were integrated into different 
chromosomes while INK4A and INK4B remained located on the same chromosome. Here 
human chromosomes and corresponding INK4 genes are shown. 
 
 
Fig. 2. Alternative splicing of p16INK4A and p14ARF. Exon E1ǂ is spliced to INK4A  
exons - E2 and E3 forming the p16 mature transcript whereas E1ǃ is alternatively spliced to 
the same E2 and E3 exons generating the mature p14ARF transcript. The latter produces a 
different protein from p16 because translation occurs from an alternative reading frame.  
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Primary melanomas, osteosarcoma and mammary tumor cell lines from dogs have been 
shown to harbor frequent loss of p16 (Levine & Fleischli, 2000; Koenig et al., 2002; 
DeInnocentes et al., 2009). Opposing roles of p16 and p14ARF have also been documented, 
where p16 inactivation attenuates senescence and ageing while p14ARF inactivation induces 
senescence and aging in skeletal muscle of BubR1 mice (Baker et al., 2008). p16 and p14ARF 
contribute to reduced growth and survival of B lymphopoiesis and inhibit malignant 
transformation (Signer et al., 2008). This contrasting behavior could be due to a level of 
tissue-specific activity of these CKIs. 
2.1 Cellular location of p16  
The subcellular localization of p16 has been even more cryptic than its genetic behavior and 
expression. Most studies have supported the localization of this protein both in the nucleus 
and the cytoplasm. But there are some debates on its specific roles, being in both cellular 
fractions, and in the context of normal and tumor cell lines. It is generally assumed that p16 is 
transported to the nucleus and acts as a CKI to regulate the G1 phase cell cycle checkpoint. 
This phenomenon has been reported in normal cells where the protein was mainly found in 
the nucleus but not in the cytoplasm (Bartkova et al., 1996). However many tumor cell lines 
have been shown to harbor p16 in the cytoplasm as well as in the nucleus (Geradts et al., 2000; 
Nilsson & Landberg, 2006). Two major populations of p16 have been identified in subcellular 
fractions – one is unphosphorylated or basic in form and the other is phosphorylated or acidic 
in form and both are generally derived from post-translational modification. The 
phosphorylated form was found to be associated with CDK4 in normal human fibroblasts 
(Gump et al., 2003). It has been reported that the localization of the two forms of p16 in both 
cellular compartments mostly depends on cancer types. In breast cancer cell lines, both forms 
of p16 were observed in the cytoplasm while the phosphorylated form was predominant in the 
nucleus (Nilsson & Landberg, 2006). In addition, strong cytoplasmic expression of p16 was 
observed in many tumor cell lines including primary breast carcinoma associated with a 
malignant phenotype (Emig et al., 1998; Evangelou et al., 2004) suggesting that the protein 
might have specific roles for its cytoplasmic localization in certain malignancies. But so far 
there is no direct evidence for the function of this tumor suppressor in the cytoplasm. One 
possible mechanism is that p16 can bind to CDK4/6 in the nucleus and the complex is 
transported to the cytoplasm, inhibiting the association of CDK4/6 with cyclinD in the nucleus 
and thereby blocking the G1/S phase transition of the cell cycle. In normal cells and epithelial-
derived breast carcinoma, a novel substrate for CDK4/6 has been identified which is more 
prevalent in the cytoplasm than in the nucleus (Kwon et al., 1995). This might cause p16 
localization bound to CDK4/6 to the cytoplasm and thus prevent CDK4/6 from acting on the 
substrate cyclinD1. Another mechanism may be hinted that p16 is mutated in some tumors 
and resulting in the defective protein being localized in the cytoplasm. However, this 
speculation is not supported by the fact that p16 is expressed in both the nucleus and the 
cytoplasm in cell lines with wild-type p16 protein (Craig et al., 1998). Other studies have 
suggested that the cytoplasmic localization might represent a mechanism for p16 inactivation 
in various tumors (Evangelou et al., 2004; Nilsson & Landberg, 2006).  
2.2 Other INK4 family CKIs – p15, p18, p19 
There are two classes of CKIs that interact with cyclin-dependent kinases (CDKs) and 
reversibly block their enzymatic activities. The first group consists of p21, p27, and p57 and 
the second group is comprised of p16/INK4A, p15/INK4B, p18/INK4C and p19/INK4D. 
www.intechopen.com
Tumor Suppressor Gene p16/INK4A/CDKN2A  
and Its Role in Cell Cycle Exit, Differentiation, and Determination of Cell Fate 
 
7 
The INK4 family CKIs (the second group) generally inhibit the assembly of CDKs by 
binding to CDK4 or CDK6 (Sherr & Roberts, 1995). Like p15/INK4B and p16/INK4A genes, 
p18/INK4C and p19/INK4D have been demonstrated to have evolved through tandem 
gene duplication and rearrangement during the course of evolution. Cross-species 
observations have suggested that a common vertebrate ancestor containing a single INK4 
gene that was duplicated and gave rise to the INK4B-INK4A and INK4C-INK4D gene 
clusters. After the divergence of mammals and other higher animals from lower vertebrates 
(~350 million years ago), further gene duplication and rearrangement resulted in the four 
different INK4 genes (Fig.1) (Gilley & Fried, 2001; Sharpless, 2005). It has been reported that 
p15 and p16 arose from a common ancestor or single gene locus placed on the same 
chromosome whereas, p18 and p19 mapped to different chromosomes in humans and other 
mammals (Guan et al., 1994; Hirai et al., 1995).  
Both p18 and p19 proteins share basic structural and biochemical properties with p15 and 
p16 proteins. All of them consist of repeated ankyrin motifs that play important roles in 
folding of proteins and in molecular interactions with other proteins such as CDK4/6 (Hirai 
et al., 1995). The p18 and p19 have not been studied as extensively as p16 and there is also 
some debate about their roles as independent tumor suppressors (Hirai et al., 1995). Unlike 
p16 and p15, which are deleted in a number of established tumor cell lines (both human and 
canine), the expression of p18 and p19 can be readily detected in many cell lines including 
many different primary tissues (Hirai et al., 1995). For example, both p18 and p19 are 
uniformly expressed in canine mammary tumor (CMT) cell lines and normal canine 
fibroblasts (NCF) (Bird et al., unpublished data). Although p15 and p16 differ significantly 
from each other as one is encoded by two exons and the other by three exons with 
alternative splicing of the first exon, respectively (Stone et al., 1995a), the two proteins are 
closely related in their structures and functions. Both have four ankyrin repeats, are 
involved in similar mechanisms of cell cycle regulation and in some instances may be 
interchangeable as tumor suppressors (Krimpenfort et al., 2007). 
Expression of p18 and p19, have been shown to predominate during early to mid-gestation in 
mouse development (Zindy et al., 1997) while expression of p15 has been found in later stages 
of gestation (Zindy et al., 1997). Circumstantially, it appears that different INK4 proteins are 
not functionally redundant as they appear to be expressed during different periods of 
development and may also be expressed in distinct tissue-specific profiles. Expression of p15 is 
down-regulated during human lymphocyte mitogenesis with a marked increase in Rb kinase 
activity providing a potential role for p15 in cell cycle arrest. p15 mediated growth suppression 
is induced by TGF mediated by SP1 and SP3 transcription factors (Li et al., 1995). p15 and p27 
levels were decreased during lymphocyte activation and appear important in maintaining cell 
quiescence (Lois et al., 1995). Although p15 acts as a tumor suppressor, the frequency of 
mutations and defects in p15 in tumor cells is lower than p16 (Stone et al., 1995a). 
Overexpression of p15 can induce cell cycle arrest in cancer cells (Thullberg et al., 2000), TGF-
mediated cell cycle arrest in human keratenocytes (HaCaT) (Hannon & Beach, 1994), and cell 
cycle arrest by the pyrido-pyrimidine derivative JTP-70902 in the human colon cancer cell line 
HT-29 (Yamaguchi et al., 2007). p18 inhibits the CDK-cyclin binding site by distorting the ATP 
binding site and by misaligning catalytic residues. p18 can also distort the cyclin-binding site 
of CDKs by reducing the size of the interface of bound cyclin (Jeffrey et al., 2000). A lack of 
mutations in p18 and p19 has been reported in tumor-derived cell lines and primary tumors, 
which were mutated for p16 and p15 expression, which shows distinct biological function of 
evolutionary related INK4 proteins (Zariwala & Xiong, 1996). 
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The INK4 and CIP cyclin dependent kinase inhibitor families have overlapping roles of cell 
cycle arrest in mouse embryo fibroblasts. Loss of both INK4 (p15, p16, and p18) and CIP 
(p21) promotes pRB inactivation, cell immortalization, and H-rasV12/c-myc-induced loss of 
contact inhibition. However, loss of both families of CKIs is still only weakly able to cause 
cell immortalization largely due to active apoptosis induction (Carbone et al., 2007). This 
data strongly supports the concept that both CKI inactivation and apoptosis failure are 
required to promote a neoplastic phenotype. 
2.3 Structure of p16 
p16 encodes four or five ankyrin repeats (Russo et al., 1998). Ankyrin repeats are 30 amino 
acid structural motifs that resemble the letter ‘L’ with a stem made of a pair of anti-parallel 
helices with a beta-hairpin region forming the base (Russo et al., 1998). The functional 
domain of p16 involved in interaction with CDK4/6, is located in the C-terminal half 
including the III and IV ankyrin repeats and the C-terminal flanking region accompanied by 
loops 2 and 3 (Fahham et al., 2010). p16 interacts with the N and C lobes of CDK6 and binds 
to one side of the catalytic cleft opposite to the cyclin binding site. CDK6 bound to p16 is 
inactive because it can not bind to cyclin and is not phosphorylated; thus, proliferation is 
suppressed (Russo et al., 1998). p16/INK4A also exerts transcriptional control over cyclin 
D1. Activating transcription factor-2 (ATF-2) and cAMP-responsive element-binding protein 
(CREB) induce the cyclinD1 expression by binding to cAMP-response element/activating 
transcription factor-2 (CRE/ATF-2) binding site at cyclinD1 promoter side, p16 represses the 
ATF-2 and CREB expression by 40-50%, thus inactivates cyclinD1 independent of its CDK4 
inactivating properties (D'Amico et al., 2004). 
2.4 p14ARF/p16gamma/p12 
As has been noted, the INK4A locus encodes two distinct p16 and p14ARF proteins. 
However, it has also been reported that besides these two proteins, this gene locus also 
encodes two additional proteins; p16gamma and p12 (Fig.3).  
p14ARF inhibits MDM2, which results in stabilization of the important tumor suppressor 
p53. p53 is a transcription factor, which activates expression of proteins required for cell-
cycle inhibition and apoptosis (Boehme & Blattner, 2009). One of the downstream regulatory 
protein activations mediated by p53 is p21 up-regulation which checks the cell cycle late in 
the G1/S phase transition. p53 also acts as a transcription repressor of other genes (Gomez-
Lazaro et al., 2004). p53 is more stable in mammary epithelial cells in comparison to 
fibroblasts in humans, which indicates the importance of p53 in mammary epithelial cell 
growth (Delmolino et al., 1993). Under normal conditions, p53 is rapidly degraded to keep 
its protein level low, mediated through the E3 ubiquitin ligase MDM2. Under conditions of 
stress or other dysfunction, p14ARF binds to MDM2, thus releasing and stabilizing p53 by 
blocking MDM2. Wild type p53-induced phosphatase 1 (Wip1/Ppm1d) stabilizes MDM2 
and downregulates p53, p38MAPK, and p16 expression (Lin et al., 2007; Yu et al., 2007). 
Disruption of Wip1 activates p53, p16, and p14ARF pathways, through p38MAPK signaling, 
and suppresses mouse embryo fibroblast transformation by oncogenes in vivo (Bulavin et al., 
2004). Another mechanism of p14ARF induction and p53 stabilization is stimulation of the 
DMP1 promoter by HER2/neu growth factor receptor overexpression (Mallakin et al., 2010). 
HER2/neu activates the DMP1 promoter through the phosphatidylinositol-3'-kinase-Akt-
NF-κB pathway, which in turn activates p14ARF transcription (Taneja et al., 2010). 
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p14ARF expression is not directly involved in the response to DNA damage although p53 
negatively regulates p14ARF expression and both of them have an inverse correlation with 
each other with respect to activity (Stott et al., 1998). Function of p14ARF is not limited to 
p53 as p14ARF also has other independent roles in cellular systems such as vascular 
regression in the developing eye (McKeller et al., 2002) and arrest of cell cycle in murine 
embryo fibroblasts in the absence of p53 (Weber et al., 2000). Loss of p14ARF, results in 
tumorigenesis by facilitating angiogenesis, which is independent of the p53 pathway 
(Ulanet & Hanahan, 2010). Other than MDM2, p14ARF also binds to E2F-1, MDMX, HIF1-, 
topoisomerase I, c-myc, and nucleophosmine (NPM) (Boehme & Blattner, 2009). p19ARF 
(the mouse homolog of human p14ARF) is able to induce cell cycle arrest in mammalian 
fibroblasts analogous to p16 (Quelle et al., 1995). 
 
 
Fig. 3. Transcription from the INK4A/ARF locus. Schematic representation of all the four 
different transcripts, transcribed from the common INK4A/ARF gene locus. p14ARF and 
p16/INK4A share exon 2 and exon 3, but differ in their first exons. p14ARF includes exon  
1ǃ while p16 includes exon 1ǂ. The stop codon for p14ARF reading frame is located in 
exon2. The stop codon for the p16/INK4A is located in exon 3. Another transcript 
transcribed from this locus is p16Ǆ, which has an extra exon (exon2Ǆ) along with all three 
exons of the p16/INK4A transcript. Exon2Ǆ (197bp) is located in intron 2 between exon 2 
and exon 3. p16Ǆ encodes a 18kDa protein. The smallest 12kDa protein encoded from 
INK4A locus is p12. p12 shares the first exon, exon1ǂ with p16, but first exon of p12 
transcribes little longer in intron 1 to give an additional 274bp sequence. Stop codon for p12 
is located in the additional intron 1ǂ sequence and introduces an earlier stop codon and 
encoding a 12kDa protein spite having a longer transcript than p16/INK4A. 
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E2F induces cell proliferation by activating S phase regulatory proteins but, according to 
one report, E2F can induce senescence in human diploid fibroblasts by inducing p14ARF 
expression, which is required for p53 stabilization (Dimri et al., 2000). Id1 encodes a helix-
loop-helix transcription factor that is overexpressed in high grade breast tumors and 
estrogen receptor-negative diseases (Gupta et al., 2007). Overexpression of Id1 or 
inactivation of the p14ARF-p53-p21 pathway can also revert senescence induced by ras 
signaling in mouse mammary carcinoma (Swarbrick et al., 2008). Other than facilitating 
the DNA-damage-induction response of p53, p14ARF also has a role in nucleotide 
excision repair. p14ARF induces expression of the damaged-DNA recognition protein 
xeroderma pigmentosum, complementation group C (XPC), by disrupting the interaction 
of E2F-4 and DRTF polypeptide 1(DP1). p14ARF also reduces the interaction of the E2F-4-
p130 repressor complex with the XPC promoter (Dominguez-Brauer et al., 2009). TGF- 
activity controls the expression of p14ARF during mouse embryonic development 
(Freeman-Anderson et al., 2009). 
Other than p16 and p14ARF transcription from the INK4A locus, there is one more 
alternative transcript that has been reported derived from this gene in human lymphoblastic 
leukemia which is termed as p16 gamma (p16)(Fig.3) (Lin et al., 2007). p16 has been 
demonstrated to be expressed at both transcriptional and translational levels confirming its 
functional potential (Lin et al., 2007). p16 shares the same exon 1, exon 2, and exon 3 as 
p16 but with a 197 bp insertion between exon 2 and 3 due to an alternative splicing event 
that extends exon 2 and concedes a stop codon. p16 is also an ankyrin-repeat protein and 
interacts with CDK4. p16 suppresses E2F activity and induces cell cycle arrest like 
p16/INK4A. It is not known what functionally distinguishes these 2 transcripts or their 
encoded proteins. 
There is an alternative splice variant of p16 present in human pancreas as well, known as 
p12 (Fig.3)(Robertson & Jones, 1999). p12 is a 12kd size protein, which is encoded from the 
same INK4/ARF locus. The p12 gene shares the p16 promoter, 5’UTR, ATG-start codon and 
exon 1, and uses the alternative splice donor site to splice to exon 2. The extra sequence 
encodes a premature stop codon that results in a smaller protein. p12 shares the first ankyrin 
repeat with p16 but is not predicted to bind to CDK4 or CDK6 based on crystal structure 
studies. p12 is reported to suppress cell growth but in a pRb-independent mechanism 
(Sharpless, 2005). When the effect of ectopic expression of all the three transcripts, p16, 
p14ARF, and p12 was compared, p16 had the most inhibitory effects on cell growth of the 
human lung cancer cell line A549 (Zhang et al., 2010b).  
3. The role of p16 
3.1 p16 as a tumor suppressor gene 
CKI p16 is an important tumor suppressor gene, defects in which are associated with cancer 
(Koh et al., 1995). p16 is functional as a growth suppressor gene as introduction of full 
length p16 cDNA caused marked growth suprression in p16-null human glioma cells (Arap 
et al., 1995), lung cancer in vitro and in vivo (Jin et al., 1995), carcinoma cell lines in vitro and 
in vivo (Spillare et al., 1996), esophageal cancer cells (Schrump et al., 1996), and human and 
canine breast cancer cells (Campbell et al., 2000; DeInnocentes et al., 2009). p16 defects are 
second in frequency only to those in p53 for human malignancies (Baylin et al., 1998). p53 
and p16 are thought to work via two independent pathways of growth suppression, but 
both of them are important in suppressing malignant transformation (Gruis et al., 1995). p16 
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gene deletions are associated with, and appear permissive for, late-stage, high-grade cancers 
such as; melanoma, bladder cancer, schistosomal bladder cancer, esophageal cancer, breast 
cancer, and glioblastoma (Gruis et al., 1995; Izumoto et al., 1995; Zhou et al., 1995; Swellam 
et al., 2004; DeInnocentes et al., 2009). Deletion of the 9p21 region encoding the p16-
INK4A/p14ARF/p15 tumor suppressor loci in humans results in tumor formation in a wide 
range of tissues (Kamb et al., 1994; Kleihues et al., 1994; Packenham et al., 1995). Loss of 
heterozygosity (Swellam et al., 2004), loss of homozygosity (Ranade et al., 1995; Quelle et al., 
1997), and hypermethylation of the promoter (Herman et al., 1997) in the 9p21 region are all 
important mechanisms which have been shown to result in loss of p16 expression and 
promote p16-related neoplasms. Hyper-methylation of the p16 promoter region appears to 
occur early in neoplastic transformation before development of tumorigenicity in rat 
respiratory epithelium (Yamada et al., 2010). Loss of p16 is associated with extended life 
span but is not sufficient for immortality (Loughran et al., 1996; Noble et al., 1996). 
Frequency of loss of p16 is high in pre-malignant lesions suggesting the importance of loss 
of p16 activity as an early event in cancer progression (Liggett & Sidransky, 1998) and 
evaluation of p16 expression could have value as an early prognostic indicator for 
predicting cancer recurrence (Bartoletti et al., 2007). Hypermethylation of CpG islands in the 
p16 promoter results in enhanced cell proliferation in human colorectal cancer and can 
activate DNA demethylation in the invasive region suppressing proliferation but enhancing 
tumor invasion (Jie et al., 2007). Additionally INK4A/ARF hypermethylation occurs 
frequently in mammary epithelial cells in high risk women with sporadic breast cancer 
(Bean et al., 2007; Jing et al., 2007; Sharma et al., 2007).  
K-cyclin (ORF72) is a human homolog of cyclinD1 in Kaposi’s sarcoma-associated 
herpesvirus (KSHV/HHV-8) which is oncogenic in immune suppressed individuals. p16 
inhibits the unphophorylated CDK6-K-cyclin complex and functional availaibility of  
K-cyclin for tumorogenesis is largely dependent upon the balance of expression of p16 and 
CDK6 (Yoshioka et al., 2010). This complex is resistant to CKI p21 and p27 and can 
phopshorylate both of them explaining the important role of p16 as a tumor suppressor 
gene in malignancies induced by KSHV and their resistance to multiple CKI activities.  
Mutations in the p16 encoding gene have also been reported in other cancer types such as 
glioblastomas, pancreatic adenocarcinomas, and melanoma-prone pedigrees. Allelic 
variants of p16 in melanoma-prone pedigrees have been found, which are deficient in 
interaction with CDK4 and CDK6. p16 allelic variants with decreased CDK interaction 
capability predisposes these individuals to increased risk of cancer which reinforces the 
important role of p16 as a tumor suppressor gene (Reymond & Brent, 1995). Mutations in 
CDK4 prevent p16 binding to CDK4 and have been identified for several noncontiguous 
amino acid sequences. This suggests there may be multiple binding sites for p16. Such 
mutated CDK4s have oncogenic potential and occur spontaneously in melanomas and other 
neoplasms (Ceha et al., 1998). 
Matrix metalloproteinases (MMPs) are the zinc-dependent endopeptidases, which are 
capable of degrading components of the extracellular matrix. The MMP family is composed 
of at least 20 enzymes. One of the MMP family enzymes is MMP-2, which has been reported 
to be strongly linked with various types of human cancers such as glioma (Uhm et al., 1996) 
and astrogliomas (Qin et al., 1998). p16 represses expression of MMP-2 and invasiveness of 
gliomas (Chintala et al., 1997) by blocking Sp1 to mediate gene transcription of MMP-2 
(Wang et al., 2006). Thus, p16 can inhibit the cyclin-CDK complex to suppress the cell cycle 
can also suppress tumor invasion through other cell regulatory functions.  
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Rab proteins are members of Ras-related small GTPase family. Rab27A is also linked with 
human genetic diseases (Seabra et al., 2002). Rab27A is associated with invasive and 
metastatic breast cancer, which is facilitated by down-regulation of p16 and up-regulation 
of cyclinD1 (Wang et al., 2008). Concomitant overexpression of p16 and p73 has oncogenic 
potential and affects the development and growth of breast carcinomas (Garcia et al., 
2004). 
Alteration of p15 and p16 expression and overexpression of TGF- are found frequently in 
schistomal bladder cancers and squamous cell carcinomas (Swellam et al., 2004). Loss of p16 
expression has prognostic value in predicting recurrence-free probability in patients affected 
by low-grade urothelial bladder cancer (Bartoletti et al., 2007). p16 has been reported to be 
inactive in human colorectal cancer but p16 expression is elevated by the demethylation of 
the p16 promoter in invasive cancer cells, as these cells cease proliferation at the invasive 
front (Jie et al., 2007).  
-catenin is the key downstream effector of Wnt signaling and is also a potent oncogene. -
catenin can also inhibit cell proliferation by activating the p14ARF-p53-p21 pathway during 
trans-differentiation of squamous cell differentiation associated with endometrial carcinoma 
(Saegusa et al., 2005). p16 is also induced along with loss of pRb expression in trans-
differentiation of endometrial carcinoma cells, mediated by -catenin and p21 (Saegusa et 
al., 2006). Deletion of p16 has been reported in high-grade B-cell non-Hodgkin’s lymphoma 
(Fosmire et al., 2007) along with increases in Rb phosphorylation at CDK4 phosphorylated 
sites. Inactivation of p16 has also been reported in high grade non-Hodgkin’s lymphoma 
and is less prevalent in low-grade tumors (Modiano et al., 2007). p16 inactivation is more 
frequent in blastoid mantle cell lymphoma (Dreyling et al., 1997). 
p16 forms a complex with HIF-1ǂ, the transcription factor for the VEGF gene promoter, thus 
represses the transactivation of VEGF. p16 inhibits VEGF gene expression and inhibits 
cancer cell induced angiogenesis in breast cancer cells and the loss of p16 is a significant 
transition in neoplastic development (Zhang et al., 2010a).  
3.2 Role of p16 in cell quiescence 
p16 checks the cell cycle at the G1/S phase transition and thus has an important role in cell 
cycle exit and quiescence in a variety of cell systems. Growth suppression by p16 depends 
upon the presence of functional Rb. Growth in Rb null fibroblasts failed to be suppressed by 
p16 (Medema et al., 1995). Ectopic p16 expression prevents re-entry into the cell cycle (Lea et 
al., 2003) and p16 expression can induce a G0-like state in hematopoietic cells (Furukawa et 
al., 2000). p16 expression is up-regulated by exposure to cellular stressors such as oxidative 
stress, aging, UV exposure, ionizing radiation, chemotherapeutic agents, telomere 
dysfunction, and wound healing (Kim & Sharpless, 2006; Natarajan et al., 2006). In response 
to non-lethal UVC irradiation, only p16 positive cell lines can induce cell cycle delay in 
comparison to p16 null cell lines (Wang et al., 1996). p16 is induced by MAPK activation, in 
response to stimulation of the ERK/MAPK pathway through RAS/RAF signaling (Ohtani et 
al., 2001). RAS activation induces p16 expression through ERK mediated activation of 
Ets1/2 (Ohtani et al., 2001) and p14ARF through Jun-mediated activation of DMP1 
(Sreeramaneni et al., 2005). Histone acetyltransferases (HATs), such as p300/CBP are 
important transcriptional up-regulators. The GC-rich region in the p16 promoter is the 
putative binding site for transcription factor Sp1 (Gizard et al., 2005). p300 in-cooperation 
with Sp1 transcriptionally upregulates p16 expression and induces cell cycle arrest in HeLa 
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cells (Kivinen et al., 1999; Wang et al., 2008). Smooth muscle cells in mature arteries in rat 
have low rates of proliferation. Suppression of proliferation is dependent on the up-
regulated levels of p16 and p27, which makes these cells unable to activate cyclinD1 and 
cyclinE and their associated kinase activties (Izzard et al., 2002). 
p16 has also been associated with a variety of additional cell proliferation control proteins 
that either bind and suppress its function or compete for p16 targets. SEI-1/p34/TRIP-Br1 
protein induces CDK4-mediated Rb phosphorylation through physical binding, 
independent of p16 (Li et al., 2005). SEI-1 facilitates CDK4 function making it resistant to p16 
inhibition. ISOC2 protein binds and co-localizes with p16 inhibiting the function of p16 
(Huang et al., 2007). Other than ISOC2, p16 protein has also been found to bind to 
proliferating cell nuclear antigen (PCNA) and minichromosome maintenance protein 6 
(MCM6) (Souza-Rodrigues et al., 2007). The same authors have reported that p16 interacts 
with DNA polymeraseǅ accessory protein PCNA, thus inhibiting the function of DNA 
polymerase. 
p16 is normally localized in the nucleus where it functions as an inhibitor of CDK/cyclin 
complexes but it has also been reported that p16 can be co-localized in the cytoplasm 
(Nilsson & Landberg, 2006) . Both cytoplasmic and nuclear p16 bind CDK6 and have a role 
in cell cycle arrest. Human melanocytes initiate differentiation by activation of the cAMP 
synthesis pathway. This results in increased association of p16 and p27 with CDK4 and 
CDK2, respectively, Rb phosphoryalation failure and decreased expression of E2F proteins 
with decreased DNA-binding activity (Haddad et al., 1999). Senescence induced by the 
cAMP pathway in these cells can be attributed to the complex formation of CKI/CDK 
complexes, which cause cell cycle exit (Haddad et al., 1999). 
It is known that p16 induces cell cycle arrest via Rb, but there is one more mechanism by 
which p16 can arrest cell cycle independent of Rb. IB is a specific inhibitor of NFB, 
which competes with p16 for binding to CDK4 and inhibits its activity (Li et al., 2003). This 
observation has led to speculation that IB could substitute for p16 in CDK4 inhibition in 
malignant cells. Other than that, in G1 phase, activity of CDKs is required for proper 
recruitment of mini-chromosome maintenance (MCM) protein to the origin recognition 
complex. p16 influences CDKs and thus influences prereplicative complex (preRC) at the 
MCM level resulting in arrest of cell cycle (Braden et al., 2006). 
c-myc is a transcription factor that plays an important role in cell proliferation. c-myc can 
induce cell cycle progression from G1 phase to S phase in quiescent cells (Eilers et al., 1991). 
Oncogenic activity of altered CDK4 is due to its inability to bind p16 and inhibiting its 
enzymic activity. The oncogenic activity of c-myc and the CDK4/cyclin D1 complex require 
each other to effectively transform cells. CDK4 requires Myc protein for proper function 
and, similary, Myc requires the CDK4 cyclinD complex kinase activity to effect tumor 
transformation. p16 inhibits the transcription regulatory activity of c-myc by blocking cyclin 
D1/CDK4 complex formation (Haas et al., 1997). 
Introduction of adenovirus expressing p16 in human cancer cell lines result in p16-mediated 
cytotoxicity and results in apoptosis (Kim et al., 2000). p16 expression and estrogen receptor 
(ER) gene expression are inversely related (Hui et al., 2000). p16 expressing adenovirus 
vector resulted in delay in tumor growth in a polyomavirus middle-T antigen model of 
murine breast carcinoma, in comparison with, p19, p27, p18, and p21 which were ineffective 
(Schreiber et al., 1999).  
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In dogs, the p16 and p14ARF transcripts derived from INK4A locus have not been fully 
elucidated. There are no full-length mRNAs or expressed sequence tags (ESTs) available that 
would completely define these transcripts. In addition this region of the chromosome is 
extremely GC-rich making it difficult to clone and sequence and causing a gap in the 
CanFam 2.0 genome assembly (Lindblad-Toh et al., 2005). The biological functions of these 
two proteins are fairly well understood compared to their genomic structure. Several lines 
of evidence suggest that both p16 and p14ARF act as potent tumor suppressors apart from 
their roles as cell cycle regulators during the G1 to S phase transition and p53 mediated cell 
cycle arrest, respectively. 
3.3 Role of p16 in cell differentiation 
Other than senescence and quiescence, p16 also has a role in cell differentiation like other 
CKIs. Expression of p16 increases by several fold in terminally differentiated human adult 
brain tissue and p16 is thought to play role in human brain development (Lois et al., 1995). 
During differentiation of human embryonic teratocarcinoma cells (NT2) into post-mitotic 
neurons, expression of p16 and p15 protein levels become elevated (Lois et al., 1995). The 
role of p16 in melanocyte differentiation has also been investigated. Microphthalmia 
transcription factor (MITF) is able to induce cell cycle arrest prior to cell differentiation by 
activation of p16 protein (Loercher et al., 2005). 
A-type lamins are intermediate filaments which affect gene expression in differentiation and 
are thought to function through an Rb-dependent mechanism. Rb associates with a number 
of tissue specific transcription factors in an E2F-independent manner and induces 
differentiation in those tissues. Rb associates with MyoD and Mef2 in skeletal muscle cells 
(Sellers et al., 1998; Novitch et al., 1999), CBFA1 and Runx2 in osteocytes (Thomas et al., 
2001; Thomas et al., 2004), and C/EBP in adipocytes and during macrophage differentiation 
(Chen et al., 1996). pRb is essential for muscle and fat cell differentiation (Korenjak & Brehm, 
2005) and cellular senescence (Ohtani et al., 2001). Cells lacking A-type lamins do not arrest 
in the presence of p16 because destabilization of pRb (Nitta et al., 2006). This report suggests 
a dependence of p16-induced cell cycle arrest on Rb and posits a role for A-type lamins in 
Rb-dependent cell cycle arrest.  
Cyclin, CDKs, and CKIs have been associated with proliferation and differentiation in a 
variety of cell and tissue systems. CyclinD1, the principle cofactor of p16, targets CDK4/6 
and may participate in myoblast differentiation (Rao & Kohtz, 1995). Thus, p16 appears to 
play a key regulatory role in cell differentiation and senescence through management of cell 
cycle exit. CDK4/6 also regulates cell division at different stages of erythroid maturation 
(Malumbres et al., 2004). CDK4 knock-out mice lack postnatal homeostasis of pituitary 
somato/lactotrophs and pancreatic B cells (Jirawatnotai et al., 2004). CDK6 knock-out mice 
have mild defects in hematopoeitic cell differentiation. Double deficiency of CDK4/6 in 
embryos appears to have no effect on organogenesis and associated cell proliferation 
although they are lethal due to defects in the erythroid lineage (Malumbres et al., 2004). 
Thus, CDK4/6 are required for many specific tissue differentiation events along with cell 
cycle progression. For example CDK4 activity is required for pancreatic -cell proliferation 
and increased expression of p16, limits the regenerative capacity of -cells with aging 
(Krishnamurthy et al., 2006).  
Cell proliferation inhibits cell differentiation while, conversely, factors inducing cell cycle 
exit often lead to differentiation. Cell cycle regulatory proteins are multifunctional and can 
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also affect cell differentiation independent of their role in cell cycle. p21 deficient cells are 
defective in differentiation although differentiation can resume by transducing cells with 
p16 to compliment the mutation (Gius et al., 1999). Cyclin-CDK complexes can inhibit 
differentiation in a kinase-dependent manner. The cyclin D1-CDK4 complex can 
phosphorylate and inhibit DMP1 or Mef2c transcription factors that are essential for 
differentiation of skeletal muscle and pre-hypertrophic chondrocytes (Hirai & Sherr, 1996; 
Lazaro et al., 2002; Arnold et al., 2007). CDK2 and CDK4 can inhibit TGF- induced growth 
arrest by phosphorylating Smad3 (Matsuura et al., 2004). p16, as a direct inhibitor of cyclin 
D1 and CDK4 complexes may thus have an indirect role in cell differentiation. 
3.4 Role of p16 in cell senescence 
Cell senescence is a permanent cell resting phase and is related to cell aging (Smith & 
Pereira-Smith, 1996). Senescence can be either induced by DNA replication stress or by 
oncogene expression but is most often the result of replicative senescence. Accumulation of 
p16 is associated with replicative senescence. Increased p16 expression has been found in 
lymphocytes only a few cell doublings before replicative senescence (Chebel et al., 2007). 
Oncogene induced senescence is linked with elevated p16 and p14ARF expression (Serrano, 
1997; Markowski et al., 2010). Deletion of the INK4/ARF gene locus, in K-ras constitutively 
expressing mice, results in loss of senescence and invasive, metastasizing tumors (Bennecke 
et al., 2010). 
p16 expression has been shown to promote premature cell senescence (Zindy et al., 1997). 
Level of p16 expression increases as mouse embryonic fibroblasts reaches senescence (Zindy et 
al., 1997). Immortal fibroblast (NIH3T3) and tumor cell lines frequently lack p16 expression 
suggesting the removal of p16 as a potential pathway to bypass senescence and also points 
towards the importance of p16 as a tumor suppressor gene (Kamb et al., 1994; Nobori et al., 
1994; Zindy et al., 1997). T box proteins (Tbx2) and polycomb proteins (BMI1, Cbx7, Mel18) 
have been reported to be repressors of all three genes of the INK4 locus (p16, p14ARF, and 
p15) (Jacobs et al., 1999; Gil et al., 2004). Repression of the INK4B/INK4A/ARF locus is 
controlled by methylation of histone 3 at lysine 27, by binding of chromobox 7(CBX7) within 
the polycomb repressive complex 1 to ANRIL (antisense non-coding RNA of 
INK4B/INK4A/ARF locus) (Yap et al., 2010). Bmi-1 encodes the polycomb protein, which 
represses both p16 and p14ARF and is linked with regulation of the replicative life span of 
human fibroblasts (Itahana et al., 2003). BMI1 protein represses p16 expression by binding 
directly to the Bmi-1 response element (BRE), within the p16 promoter (Meng et al., 2010), and 
is dependent on the continued presence of EZH2-containing Polycomb-Repressive Complex 2 
(PRC2) complex (Bracken et al., 2007). Enhancer of zeste homolog 2 (EZH2) is a histone 
methyltransferase and a component of the polycomb group protein complex which represses 
INK4a/ARF gene expression in pancreatic islet beta cells (Chen et al., 2009).  
Under a stress and senescence stimulus EZH2 levels decrease coinciding with up-regulated 
p16. Coincidently PRC2 and PRC1 complexes, localized at the regulatory domain of p16, are 
lost when cells enter senescence which in turn results in decreased levels of histone H3K27 
trimethylation (H3K27me3) and increased levels of the histone demethylase Jmjd3 with the 
recruitment of the MLL1 protein (Agherbi et al., 2009). Polycomb proteins are recruited to 
the INK4/ARF locus through CDC6 and, upon senescence and with an increase in Jmjd3 
levels, MLL1 protein is recruited to the locus provoking dissociation of polycomb protein 
from the INK4/ARF locus. This leads to transcription and replication of the INK4/ARF locus 
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in early S phase prior to reaching senescence (Agherbi et al., 2009). CDC6 is an essential DNA 
replication regulator. CDC6 overexpression induces increased INK4/ARF tumor suppressor 
gene expression through epigenetic modification of chromatin at the INK4/ARF locus 
(Borlado & Mendez, 2008). COOH–terminal-binding protein (CtBP), a physiologically 
regulated co-repressor, has also been reported to have a significant role in p16 repression. 
Several of the pathways noted above repress p16 via CtBP-mediated repression as CtBP forms 
bridges between proteins having PxDLS amino acid motifs including several transcription 
factors and other proteins involved in transcription (Mroz et al., 2008). 
The levels of p27 and p16 proteins are significantly increased in contact-inhibited human 
fibroblasts while in contrast, levels were low in serum-deprived human fibroblasts but in 
both cases, even through the mechanisms of growth arrest are different, they both affect the 
same pathway involving CDK4, cyclin D1, and Rb (Dietrich et al., 1997). Maintenance of p16 
and p27 levels have also been shown to contribute to the low levels of proliferation in 
normal blood vessels (Izzard et al., 2002) and p16 mRNA and protein accumulate in human 
fibroblasts as they become senescent (Hara et al., 1996).  
4. Potential of p16 as a therapeutic or gene therapy target 
p16 is an important tumor suppressor gene, deletion of which causes various types of 
tumors making it an important potential target for cancer gene therapy. It has been reported 
that p16 positive oropharyngeal squamous cell carcinoma (OPSCC) patients respond more 
favorably to intensity-modulated radiotherapy treatment in comparison to similar p16 
negative tumors (Shoushtari et al., 2010). Infectious delivery of the whole p15/p16/p14ARF 
locus, in infectious bacterial artificial chromosomes, results in growth suppression in human 
glioma cells (Inoue et al., 2004). Induction of p16 using the DNA methyltransferase inhibitor 
zebularine combined with the histone deacetylation (HDAC) inhibitors depsipeptide led to 
inhibition of cell growth in lung tumor cell lines (Chen et al., 2010). Ectopic p16 introduction 
in cancer cells alone or with other tumor suppressor genes inhibits cell growth and induces 
apoptosis and senescence, while p16 gene silencing reduced the p53-mediated response to 
chemotherapeutic agents in cancers (Derenzini et al., 2009). Histone methyltransferase EZH2 
inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat together 
induce p16, p21, p27, and FBX032 and down-regulates cyclin E and HOXA9 levels, which 
induces apoptosis in cultured and primary human acute myeloid leukemia (AML) cell line 
cells (Fiskus et al., 2009). p16 along with the murine granulocyte-macrophage colony-
stimulating factor gene (AdGM-CSF) can induce effective anti-tumor immunity (Wang et al., 
2002). Exogenous expression of p16 and p53 induce apoptosis in lung carcinoma cells (Bai et 
al., 2000), leukemia cell line K562 (Rui & Su, 2002), non-small lung cancer (Wu et al., 2000), 
and pancreatic cancer (Ghaneh et al., 2001). p16 along with p27 inhibits angioplasty-induced 
neointimal hyperplasia and coronary artery occlusion (Tsui et al., 2001), inhibits 
proliferation in neointimal hyperplasia (McArthur et al., 2001), and a wide range of other 
tumor types (Patel et al., 2000). Ectopic expression of p16 by replication-competent 
adenovirus leads to potent anti-tumor effects in gastric cancer xenografts in nude mice (Ma 
et al., 2009) while p16 transfection along with cisplatin treatment increased senescence and 
growth inhibition in non-small cell lung cancer xenografts in mice (Fang et al., 2007). Ectopic 
p16 expression was able to induce growth arrest in pancreatic carcinoma JF305 cell lines (Ma 
et al., 2007), human laryngeal squamous cell carcinoma (Liu et al., 2003; Fu et al., 2004), and 
inhibit experimental lung metastasis in Balb/c nude mice (Kim et al., 2003), inhibit cell 
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growth in nasopharyngeal carcinoma (Lee et al., 2003), and a murine model of head and 
neck cancer (Rhee et al., 2003), human mesothelioma (Yang et al., 2003), and suppress tumor 
growth by glioblastoma cells in vivo and in vitro (Adachi et al., 2002). p16 transfection 
suppressed growth of Bcap-37 breast cancer cells (Bai et al., 2001), the human melanoma cell 
line WM-983A (Cheng et al., 1999), human lung adenocarcinomas (Fu et al., 1999), 
pancreatic cancer (Calbo et al., 2001), and inhibits cardiac hypertrophy in vitro and in vivo 
(Nozato et al., 2001). p16 also inhibited cell growth in a human ovarian cancer cell line 
(Wang et al., 1999), a human gastric cell line (Sun & Lu, 1997), and a small cell lung 
carcinoma (Sumitomo et al., 1999). All of these diverse examples demonstrate the potent and 
broadly efficient effects of exogenous p16 expression on cell proliferation in p16 negative 
cancer cells in vitro and in vivo and reflects the importance of p16 as regulatory factor and 
potential target for gene therapy and cancer therapeutics. 
5. Conclusions 
p16/INK4A/CDKN2A is an important tumor suppressor gene, which is required for the 
control of unregulated cell growth in many and perhaps most cell types. The INK4A locus is 
also unique in eukaryotes, where 3 and perhaps 4 transcripts are derived which have similar 
functions of suppressing cell growth but that work via very different pathways. Most 
surprising is the utilization of alternative open reading frames from a single gene complex 
mandating co-evolution of the unrelated protein sequences. Despite these constraints, 
mutation of p16 is second only to p53 in mutation frequency in a wide range of tumors. This 
strongly suggests that p16 may have real potential as an important new target for cancer 
gene therapy. p16 is not just an important cell cycle regulatory protein that helps suppress 
the cell growth and tumor formation, p16 also has a role in other cell cycle phases. p16 has 
been reported to play an important role in cell differentiation, cell quiescence, and cell 
senescence, which makes it not just a tumor suppressor protein but a cell regulatory protein 
that plays a critical role in regulating terminal differentiation and the aging process. There is 
a great need to investigate all the subtleties surrounding p16 function and to unravel all the 
pathways and binding partners of p16. p16 is a promising gene located within a complex 
gene locus with many roles in cell metabolism.  
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